Direct acting oral anticoagulants (DOACs) in critically ill patients.

Direct acting oral anticoagulants (DOACs) in critically ill patients.
Chest. 2019 Jun 25;:
Authors: Rali P, Gangemi A, Moores A, Mohrien K, Moores L
Abstract
The direct acting oral anticoagulants (DOACs) have been increasingly utilized over vitamin K antagonists (VKA) in recent years because they do not require monitoring and have an immediate anti-coagulation effect. In general, DOACs have shown a better safety profile and non-inferiority for venous thromboembolism (VTE) prophylaxis and treatment, and stroke prevention in patients with atrial fibrillation, when compared to VKA agents in the non-ICU population. Whether this holds true in patients who are critically ill remains unknown. In this review, we will address the role of DOACs in special ICU populations, use of these agents for VTE prophylaxis, perioperative management of DOACs, drug monitoring and potential drug interactions of DOACs in critically ill patients. Adverse events, and and available reversal agents for DOACs will also be discussed.
PMID: 31251908 [PubMed - as supplied by publisher]

Source: Chest - June 24, 2019 Category: Respiratory Medicine Authors: Rali P, Gangemi A, Moores A, Mohrien K, Moores L Tags: Chest Source Type: research